Skip to main content
GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion

Consider TIPS in Treating Portal Hypertension

Earlier TIPS procedure with controlled expansion endoprosthesis

GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion combines the legacy of proven patency1 with diameter control to reach a targeted portal pressure gradient. The innovations include:

  • Control the diameter — Designed to reach a targeted portal pressure gradient
  • Lasting diameter control* — Size and set the diameter to stay
  • Engineered for flexibility — Conformability to tortuous anatomy

GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion specifications

Device specifications: Features and benefits

Improving and extending life for over 20 years

With 20 years of expertise and improved outcomes, GORE® VIATORR® Devices are at the forefront of extending life for patients with complications due to liver cirrhosis.

READ MORE

Long-term experience with the GORE® VIATORR® Devices

For your patients with portal hypertension, the GORE® VIATORR® TIPS Endoprosthesis maintains significantly increased patency compared to bare metal stent alternatives. Highly effective in lowering portal pressure gradients in patients with refractory ascites and variceal bleeding, the GORE® VIATORR® TIPS Endoprosthesis offers an effective treatment option for patients over a longer period of time. The GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion allows doctors to adjust the diameter of the device during implantation based on the patient’s needs and portal pressure.

Two clinical studies were conducted in the United States to evaluate the GORE® VIATORR® TIPS Endoprosthesis and the BOSTON SCIENTIFIC WALLSTENT Endoprosthesis Stent for use in de novo TIPS and TIPS revision. These studies demonstrated that primary patency of the GORE® VIATORR® Device group was superior to that of the BOSTON SCIENTIFIC WALLSTENT Device group (P < .001) at six months, with no significant differences in mortality or risk of encephalopathy.

Gore products referenced within are used within their FDA approved/cleared indications or are under investigation for the uses referenced within. Gore does not have knowledge of the indications and FDA approval/clearance status of non-Gore products. Gore makes no representations as to the surgical techniques, medical conditions or other factors that may be described in the article. The reader is advised to contact the manufacturer for current and accurate information.

This information is intended for education and awareness only. Patients should consult their physician for information on the risks associated with the devices and surgical procedures discussed in this website. All surgical procedures carry potential health risks. Not all patients will be candidates for treatment with these devices, and individual outcomes may vary.

Always follow physician advice on your post-surgery care and recovery.

Refer to Instructions for Use at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. RX Only

eIFU Symbol

Footnotes & References

* Based on benchtop data on file. Less than 0.25 mm increase in diameter (diameter expansion) demonstrated by a simulated 10 year period at physiologic portal pressures.

 On file with Gore PMA P040027.

  1. Bureau C, Pagan JCG, Layrargues GP, et al.  Patency of stents covered with polytetrafluoroethylene in patients treated by transjugular intrahepatic portosystemic shunts: long term results of a randomized multicentre study.  Liver International 2007;27(6):742-747.

BOSTON SCIENTIFIC and WALLSTENT are trademarks of Boston Scientific Corporation.

22730172-EN